FDA Approves Actemra For the Treatment of Rheumatoid Arthritis
FLINT, Mich.— Nov. 07, 2013 —On Monday, October 21, 2013, the U.S. Food and Drug Administration approved a subcutaneous formulation of Actemra® (tocilizumab). This new product was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Methotrexate is an example of a DMARD. Tocilizumab may be used alone or as a component of a combination therapy regimen consisting of methotrexate or other non-biologic DMARDs. The subcutaneous product will be available as 162 mg single-use prefilled syringes. The product is expected to be available in November 2013.
Actemra® was previously approved as an intravenous (IV) infusion for the treatment of RA, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). Diplomat will be able to distribute this medication when it is available.
For more information about our support services for patients with rheumatoid arthritis, visit our website. You may also contact us directly at 877.977.9118 or, if your inquiry is not urgent, email us at email@example.com.
@DiplomatRxWe are #hiring sales consultants for both NYC and Oakland, California! Come check it out. https://t.co/GDqMaItrsZ5 days ago
@gchabitatRT @gchabitat: Do you have what it takes to be a Habitat Olympian? Join us at @DiplomatRx on 5/5 to find out! https://t.co/5eq5y94hv36 days ago
@DiplomatRxDiplomat Will Dispense ZEJULA™ to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer… https://t.co/MnQRQdLufl1 week ago
@DiplomatRxFar more than an adventure, their trip was dedicated to assisting people living with #hemophilia… https://t.co/kngmnkvjvU2 weeks ago
@DiplomatRxDiplomat to Release First Quarter 2017 Operating Results and Host Conference Call on Monday, May 8, 2017… https://t.co/h6vJR7823O2 weeks ago